Mergers & acquisitions news

Expert Advice 2 Mar 2023

5 steps to strategic partnerships for healthtech startups

By Varvara Melikhova, founder and CEO of Unison Innovations Strategic partnerships are a better way to build a product’s capabilities than outright acquisitions. While the M&A path is set out for the most mature successful startups, early-stage partnerships can enhance a product’s market value and provide access to Big Pharma expertise and infrastructure, which significantly […]

March 2, 2023 - 6 minutesmins - By External Contributor

News and Trends 28 Feb 2023

GC Biopharma acquiring hemophilia rare disease pipeline

GC Biopharma Corp., a South Korean provider of biopharmaceutical products, has signed an asset purchase agreement with Catalyst Biosciences to acquire three programs related to the orphan hematology disorders. The agreement includes Marzeptacog alfa (MarzAA), an engineered factor VIIa, which is ready for phase 3 clinical stage development. In its previous clinical development trials, MarzAA […]

February 28, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 2 Feb 2023

Crown Bioscience acquiring Indivumed’s service business and biobank

Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, has entered into an agreement to acquire the IndivuServ business unit of Indivumed GmbH. A share purchase agreement (SPA) between was executed in December, 2022, and subject to customary closing adjustments, the transaction is expected to close in April 2023. Indivumed […]

February 2, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 11 Jan 2023

Five key trends shaping life sciences in 2023

By Kevin Wayer, president – government, education, infrastructure and life sciences industries, JLL, and Travis McCready, head of life sciences, industries Americas, JLL After an unprecedented period of growth during the pandemic, life sciences activity normalized in 2022. The life sciences industry has not been immune to the macroeconomic challenges plaguing the global economy, but […]

January 11, 2023 - 5 minutesmins - By External Contributor

News and Trends 11 Jan 2023

Clinical trends for 2023

By Richard Staines, account director, Optimum Strategic Communications Few would deny that the decade has had a turbulent start, but after the tragedies of the COVID-19 pandemic and the Ukraine war, there’s hope that 2023 will see a new wave of clinical research. Exciting new technologies such as gene editing, gene therapy and a next […]

January 11, 2023 - 8 minutesmins - By External Contributor

News and Trends 11 Jan 2023

What’s in store for biotech in 2023?

Perhaps 2022 will best be remembered in the life science industry for the return of many of the face-to-face events that fell by the wayside during the COVID-19 pandemic. It might have been a mixed year for biotech companies, but 2023 is a new year, with new challenges, but also new opportunities. So what do […]

January 11, 2023 - 14 minutesmins - By Jim Cornall

News and Trends 6 Jan 2023

Ensoma acquiring Twelve Bio

Arix Bioscience, a global venture capital company focused on investing in breakthrough biotechnology companies, announced that portfolio company Twelve Bio will be acquired by Ensoma in connection with an $85 million financing of Ensoma which Arix co-led, investing $9 million. Twelve Bio is a gene editing company pioneering the therapeutic application of next-generation CRISPR-Cas medicines. […]

January 6, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 3 Jan 2023

Blacksmith Medicines merging with Forge Therapeutics

Blacksmith Medicines, Inc., and Forge Therapeutics have signed a definitive merger agreement. This will create a biopharma company dedicated to discovering and developing medicines targeting a large class of proteins called metalloenzymes. The initial focus will be on oncology and infection. “We are excited to unveil the merger of Blacksmith and Forge, which we believe […]

January 3, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 19 Dec 2022

Prenetics acquires ACT Genomics

Prenetics Global Limited is acquiring a majority stake in ACT Genomics Holdings Company Limited, an Asia based genomics company specializing in precision oncology with operations in Hong Kong, Taiwan, Japan, Singapore, Thailand and in the U.K. “With the addition of ACT’s technologies, capabilities and team, Prenetics will be well-positioned to accelerate the utilization of genetic […]

December 19, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 8 Dec 2022

Polyplus announces completion of acquisition of Xpress Biologics to expand plasmid DNA

Polyplus has announced the completion of an acquisition of Belgian Xpress Biologics to expand plasmid DNA technology. Xpress Biologics specializes in the production of plasmid DNA and protein using microbial expression systems. Polypus concentrates on the manufacturing of advanced therapeutic medicinal products from research to commercial grade. The acquisition will strategically expand the Polyplus plasmid […]

December 8, 2022 - 2 minutesmins - By Liza Laws

News and Trends 5 Dec 2022

New company Liminatus Pharma Inc to develop three cancer treatments

Clinical-stage biopharma company Liminatus Pharma LLC and Iris Acquisition Corp, a publicly traded special purpose acquisition company formed for the purpose of acquiring or merging with one or more businesses, announced they have entered into a definitive business combination agreement. Upon closing of the transaction, the combined company will be renamed Liminatus Pharma, Inc.. The […]

December 5, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 2 Dec 2022

Full-Life Technologies acquiring Focus-X Therapeutics

Full-Life Technologies, a global radiotherapeutics company, is acquiring New Jersey-based Focus-X Therapeutics, a company developing targeted radiopharmaceuticals to treat cancer based on peptide engineering technology. The acquisition expands Full-Life’s pipeline, including two compounds nearing clinical trials, provides a second innovative peptide focused discovery platform, and leverages its radiotechnology manufacturing and logistics platforms to advance compounds […]

December 2, 2022 - 2 minutesmins - By Jim Cornall

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Mergers & acquisitions

5 steps to strategic partnerships for healthtech startups

GC Biopharma acquiring hemophilia rare disease pipeline

Crown Bioscience acquiring Indivumed’s service business and biobank

Five key trends shaping life sciences in 2023

Clinical trends for 2023

What’s in store for biotech in 2023?

Ensoma acquiring Twelve Bio

Blacksmith Medicines merging with Forge Therapeutics

Prenetics acquires ACT Genomics

Polyplus announces completion of acquisition of Xpress Biologics to expand plasmid DNA

New company Liminatus Pharma Inc to develop three cancer treatments

Full-Life Technologies acquiring Focus-X Therapeutics

Subscribe to our newsletter to get the latest biotech news!